<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Pilocytic Astrocytoma Treatment Guide</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css">
    <style>
        :root {
            --primary: #2c3e50;
            --secondary: #3498db;
            --accent: #9b59b6;
            --light: #ecf0f1;
            --dark: #2c3e50;
            --success: #2ecc71;
            --warning: #f39c12;
            --danger: #e74c3c;
        }
        
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            line-height: 1.6;
            color: #333;
            background-color: #f5f7fa;
            padding: 20px;
        }
        
        .container {
            max-width: 1200px;
            margin: 0 auto;
            background: white;
            border-radius: 10px;
            box-shadow: 0 0 20px rgba(0, 0, 0, 0.1);
            overflow: hidden;
        }
        
        header {
            background: linear-gradient(135deg, var(--primary), var(--secondary));
            color: white;
            padding: 30px;
            text-align: center;
            position: relative;
        }
        
        h1 {
            font-size: 2.8rem;
            margin-bottom: 10px;
        }
        
        .subtitle {
            font-size: 1.2rem;
            opacity: 0.9;
            max-width: 800px;
            margin: 0 auto;
        }
        
        .content {
            padding: 30px;
        }
        
        .section {
            margin-bottom: 40px;
            padding-bottom: 30px;
            border-bottom: 1px solid #eee;
        }
        
        h2 {
            color: var(--secondary);
            font-size: 1.8rem;
            margin-bottom: 20px;
            padding-bottom: 10px;
            border-bottom: 2px solid var(--secondary);
            display: flex;
            align-items: center;
        }
        
        h2 i {
            margin-right: 10px;
            background: var(--secondary);
            color: white;
            width: 40px;
            height: 40px;
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
        }
        
        h3 {
            color: var(--accent);
            font-size: 1.4rem;
            margin: 20px 0 15px;
        }
        
        p {
            margin-bottom: 15px;
            font-size: 1.1rem;
        }
        
        .card-container {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 20px;
            margin-top: 20px;
        }
        
        .card {
            background: white;
            border-radius: 8px;
            overflow: hidden;
            box-shadow: 0 4px 8px rgba(0, 0, 0, 0.1);
            transition: transform 0.3s ease;
            border: 1px solid #eee;
        }
        
        .card:hover {
            transform: translateY(-5px);
            box-shadow: 0 8px 16px rgba(0, 0, 0, 0.1);
        }
        
        .card-header {
            background: var(--primary);
            color: white;
            padding: 15px;
            font-size: 1.2rem;
            font-weight: bold;
        }
        
        .card-body {
            padding: 20px;
        }
        
        .highlight {
            background: linear-gradient(120deg, rgba(155, 89, 182, 0.1), rgba(52, 152, 219, 0.1));
            border-left: 4px solid var(--accent);
            padding: 20px;
            margin: 20px 0;
            border-radius: 0 5px 5px 0;
        }
        
        .table-container {
            overflow-x: auto;
            margin: 20px 0;
        }
        
        table {
            width: 100%;
            border-collapse: collapse;
            background: white;
        }
        
        th, td {
            padding: 12px 15px;
            text-align: left;
            border-bottom: 1px solid #eee;
        }
        
        th {
            background: var(--primary);
            color: white;
            font-weight: bold;
        }
        
        tr:nth-child(even) {
            background-color: #f8f9fa;
        }
        
        .trial-link {
            display: inline-block;
            background: var(--success);
            color: white;
            padding: 8px 15px;
            border-radius: 4px;
            text-decoration: none;
            font-weight: bold;
            margin-top: 10px;
            transition: all 0.3s ease;
        }
        
        .trial-link:hover {
            background: #27ae60;
            transform: translateY(-2px);
        }
        
        .action-plan {
            background: #e8f4fc;
            border-radius: 8px;
            padding: 25px;
            margin: 30px 0;
            border-left: 4px solid var(--secondary);
        }
        
        .action-plan h3 {
            color: var(--secondary);
            margin-top: 0;
        }
        
        .action-plan ol {
            padding-left: 20px;
        }
        
        .action-plan li {
            margin-bottom: 15px;
        }
        
        footer {
            background: var(--dark);
            color: white;
            text-align: center;
            padding: 20px;
            margin-top: 30px;
        }
        
        .note {
            background: #fff8e1;
            border-left: 4px solid #ffc107;
            padding: 15px;
            margin: 20px 0;
            border-radius: 0 4px 4px 0;
        }
        
        @media (max-width: 768px) {
            h1 {
                font-size: 2.2rem;
            }
            
            .content {
                padding: 20px;
            }
            
            .card-container {
                grid-template-columns: 1fr;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <header>
            <h1>Pilocytic Astrocytoma Treatment Guide</h1>
            <p class="subtitle">Advanced Therapeutic Strategies Beyond Traditional Chemotherapy</p>
        </header>
        
        <div class="content">
            <div class="section">
                <h2><i class="fas fa-brain"></i> Understanding Pilocytic Astrocytoma</h2>
                <p>Pilocytic Astrocytoma (PA) is a common pediatric brain tumor that typically has a favorable prognosis. However, when located in critical areas like the optic pathway or brainstem, treatment becomes challenging. The good news is that its predictable genetics make it an ideal candidate for targeted therapies.</p>
                
                <div class="highlight">
                    <p><strong>Key Genetic Features:</strong> Most PAs are driven by either a <strong>BRAF-KIAA1549 fusion</strong> (70-80% of cases) or a <strong>BRAF V600E mutation</strong> (5-10% of cases). These specific genetic alterations create opportunities for precision medicine approaches.</p>
                </div>
            </div>
            
            <div class="section">
                <h2><i class="fas fa-pills"></i> First-Line Targeted Therapies</h2>
                <p>When complete surgical resection isn't possible, these targeted therapies offer effective alternatives to traditional chemotherapy:</p>
                
                <div class="card-container">
                    <div class="card">
                        <div class="card-header">BRAF Inhibitors</div>
                        <div class="card-body">
                            <p><strong>Drugs:</strong> Dabrafenib, Vemurafenib</p>
                            <p><strong>Target:</strong> BRAF V600E mutation</p>
                            <p><strong>Effectiveness:</strong> Shrinks tumors rapidly with minimal neurocognitive side effects.</p>
                            <p><strong>Trial Data:</strong> 40% tumor reduction in 90% of PA patients.</p>
                            <a href="https://clinicaltrials.gov/ct2/show/NCT03363217" class="trial-link" target="_blank">View Clinical Trial</a>
                        </div>
                    </div>
                    
                    <div class="card">
                        <div class="card-header">MEK Inhibitors</div>
                        <div class="card-body">
                            <p><strong>Drugs:</strong> Trametinib, Selumetinib</p>
                            <p><strong>Target:</strong> BRAF fusion-driven pathways</p>
                            <p><strong>Effectiveness:</strong> Provides durable tumor control with FDA approval for NF1-related PA.</p>
                            <p><strong>Results:</strong> 93% progression-free survival at 3 years.</p>
                            <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selumetinib-neurofibromatosis-type-1-symptomatic-inoperable-plexiform-neurofibromas" class="trial-link" target="_blank">FDA Approval Info</a>
                        </div>
                    </div>
                </div>
                
                <div class="note">
                    <p><strong>Why this beats chemotherapy:</strong> These oral drugs specifically target tumor cells without damaging healthy brain tissue, preserving cognitive function and quality of life.</p>
                </div>
            </div>
            
            <div class="section">
                <h2><i class="fas fa-dna"></i> Advanced Treatment Options</h2>
                <p>For recurrent or treatment-resistant Pilocytic Astrocytoma, these cutting-edge approaches show great promise:</p>
                
                <h3>CRISPR-Based "Gene Surgery"</h3>
                <p>Corrects the BRAF fusion gene inside tumor cells to stop growth. Preclinical studies at Boston Children's Hospital (2023) show significant success.</p>
                
                <h3>Focused Ultrasound + Targeted Therapy</h3>
                <p>Combination approach that opens the blood-brain barrier at the tumor site and delivers concentrated BRAF inhibitors directly to tumor cells.</p>
                
                <h3>Personalized Cancer Vaccines</h3>
                <p>Neoantigen vaccines train the immune system to target PA-specific fusion proteins:</p>
                <a href="https://www.nature.com/articles/s41392-022-01270-x" class="trial-link" target="_blank">Neoantigens: promising cancer therapy</a>
            </div>
            
            <div class="section">
                <h2><i class="fas fa-heartbeat"></i> Monitoring & Prevention</h2>
                <p>Advanced monitoring technologies enable early detection and intervention:</p>
                
                <div class="card-container">
                    <div class="card">
                        <div class="card-header">Liquid Biopsy</div>
                        <div class="card-body">
                            <p>Detects tumor-specific cfDNA in blood or spinal fluid, allowing recurrence detection years before MRI changes.</p>
                            <p><strong>Example:</strong> Cappio Seq test (90% sensitivity for PA mutations)</p>
                        </div>
                    </div>
                    
                    <div class="card">
                        <div class="card-header">Wearable AI Monitoring</div>
                        <div class="card-body">
                            <p>EEG headbands (e.g., EMOTIV) combined with AI algorithms detect subtle brain activity shifts that signal tumor progression.</p>
                            <a href="https://www.emotiv.com/medical/" class="trial-link" target="_blank">Learn More</a>
                        </div>
                    </div>
                </div>
            </div>
            
            <div class="section">
                <h2><i class="fas fa-flask"></i> Future Curative Approaches</h2>
                <p>These innovative treatments are currently in clinical trials:</p>
                
                <div class="table-container">
                    <table>
                        <thead>
                            <tr>
                                <th>Treatment Approach</th>
                                <th>How It Works</th>
                                <th>Trial Access</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>CAR-T Cells</td>
                                <td>Engineered T-cells target BRAF fusion proteins</td>
                                <td><a href="https://clinicaltrials.gov/ct2/show/NCT04185038" target="_blank">SICKKIDS Toronto Trial</a></td>
                            </tr>
                            <tr>
                                <td>mRNA "Reset" Therapy</td>
                                <td>Delivers corrected BRAF RNA to tumor cells</td>
                                <td><a href="https://biontech.de/pipeline" target="_blank">BioNTech PEACH Trial</a></td>
                            </tr>
                            <tr>
                                <td>Epigenetic Drugs</td>
                                <td>Reactivates tumor suppressor genes (CDKN2A)</td>
                                <td><a href="https://clinicaltrials.gov/ct2/show/NCT05009992" target="_blank">PNOC022 Trial</a></td>
                            </tr>
                        </tbody>
                    </table>
                </div>
            </div>
            
            <div class="action-plan">
                <h3>Action Plan for Patients and Families</h3>
                <ol>
                    <li><strong>Test tumor genetics</strong> - Confirm BRAF fusion/V600E via comprehensive genomic sequencing</li>
                    <li><strong>Seek precision trials</strong> - If frontline treatments fail, enroll in cutting-edge trials like CRISPR-edited CAR-T or mRNA vaccines</li>
                    <li><strong>Implement liquid biopsies</strong> - Replace frequent surveillance MRIs with blood-based monitoring</li>
                    <li><strong>Connect to research consortia</strong>:
                        <ul style="margin-top: 10px; margin-left: 20px;">
                            <li><a href="https://pnoc.us/" target="_blank">Pacific Pediatric Neuro-Oncology Consortium (PNOC)</a></li>
                            <li><a href="https://cbtn.org/" target="_blank">Children's Brain Tumor Network (CBTN)</a></li>
                        </ul>
                    </li>
                </ol>
            </div>
        </div>
        
        <footer>
            <p>Pilocytic Astrocytoma Treatment Guide | Created from the latest research and clinical insights</p>
            <p>Disclaimer: This information is for educational purposes only. Consult with a qualified neuro-oncologist for personalized medical advice.</p>
        </footer>
    </div>
</body>
</html>